Nektar Therapeutics

Symbol: NKTR

NASDAQ

0.9

USD

Market price today

  • -1.1073

    P/E Ratio

  • -0.0158

    PEG Ratio

  • 165.26M

    MRK Cap

  • 0.00%

    DIV Yield

Nektar Therapeutics (NKTR) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.63%

Operating Profit Margin

-1.81%

Net Profit Margin

-3.06%

Return on Assets

-0.69%

Return on Equity

-1.52%

Return on Capital Employed

-0.47%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Howard W. Robin
Full-time employees:137
City:San Francisco
Address:455 Mission Bay Boulevard South
IPO:1994-05-03
CIK:0000906709

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.625% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -1.810%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -3.063%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.694% return, is a testament to Nektar Therapeutics's adeptness in optimizing resource deployment. Nektar Therapeutics's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.516%. Furthermore, the proficiency of Nektar Therapeutics in capital utilization is underscored by a remarkable -0.470% return on capital employed.

Stock Prices

Nektar Therapeutics's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.65, while its low point bottomed out at $1.45. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Nektar Therapeutics's stock market.

Liquidity Ratios

Analyzing NKTR liquidity ratios reveals its financial health of the firm. The current ratio of 645.03% gauges short-term asset coverage for liabilities. The quick ratio (596.59%) assesses immediate liquidity, while the cash ratio (39.32%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio645.03%
Quick Ratio596.59%
Cash Ratio39.32%

Profitability Ratios

NKTR profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -306.54% underscores its earnings before tax deductions. The effective tax rate stands at 0.07%, revealing its tax efficiency. The net income per EBT, 99.93%, and the EBT per EBIT, 169.34%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -181.02%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-306.54%
Effective Tax Rate0.07%
Net Income per EBT99.93%
EBT per EBIT169.34%
EBIT per Revenue-181.02%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 6.45, it details the span from stock purchase to revenue. The 6 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding597
Days of Inventory Outstanding174
Operating Cycle183.16
Days of Payables Outstanding106
Cash Conversion Cycle77
Receivables Turnover40.02
Payables Turnover3.43
Inventory Turnover2.10
Fixed Asset Turnover2.44
Asset Turnover0.23

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.01, and free cash flow per share, -1.01, depict cash generation on a per-share basis. The cash per share value, 1.59, showcases liquidity position. Lastly, the operating cash flow sales ratio, -2.14, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.01
Free Cash Flow per Share-1.01
Cash per Share1.59
Operating Cash Flow Sales Ratio-2.14
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-1.46
Short Term Coverage Ratio-10.00
Capital Expenditure Coverage Ratio-222.67
Dividend Paid and Capex Coverage Ratio-222.67

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 33.13%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.01, we discern the balance between debt and equity financing. The long-term debt to capitalization, 46.23%, and total debt to capitalization, 50.17%, ratios shed light on its capital structure. An interest coverage of -6.44 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio33.13%
Debt Equity Ratio1.01
Long Term Debt to Capitalization46.23%
Total Debt to Capitalization50.17%
Interest Coverage-6.44
Cash Flow to Debt Ratio-1.46
Company Equity Multiplier3.04

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.47, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.45, reflects the portion of profit attributed to each share. The book value per share, 0.69, represents the net asset value distributed per share, while the tangible book value per share, 0.69, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.47
Net Income Per Share-1.45
Book Value Per Share0.69
Tangible Book Value Per Share0.69
Shareholders Equity Per Share0.69
Interest Debt Per Share0.83

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -2.10%, indicates top-line expansion, while the gross profit growth, -24.06%, reveals profitability trends. EBIT growth, 42.80%, and operating income growth, 42.80%, offer insights into operational profitability progression. The net income growth, 25.03%, showcases bottom-line expansion, and the EPS growth, 26.40%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-2.10%
Gross Profit Growth-24.06%
EBIT Growth42.80%
Operating Income Growth42.80%
Net Income Growth25.03%
EPS Growth26.40%
EPS Diluted Growth26.40%
Weighted Average Shares Growth1.53%
Weighted Average Shares Diluted Growth1.53%
Operating Cash Flow Growth36.64%
Free Cash Flow Growth37.53%
10-Year Revenue Growth per Share-63.14%
5-Year Revenue Growth per Share-92.84%
3-Year Revenue Growth per Share-44.61%
10-Year Operating CF Growth per Share-204.51%
5-Year Operating CF Growth per Share-125.42%
3-Year Operating CF Growth per Share42.22%
10-Year Net Income Growth per Share-3.79%
5-Year Net Income Growth per Share-138.41%
3-Year Net Income Growth per Share41.62%
10-Year Shareholders Equity Growth per Share188.75%
5-Year Shareholders Equity Growth per Share-92.77%
3-Year Shareholders Equity Growth per Share-88.57%
Receivables Growth-62.35%
Inventory Growth-16.15%
Asset Growth-43.99%
Book Value per Share Growth-64.81%
Debt Growth75.22%
R&D Expense Growth-49.03%
SGA Expenses Growth-13.77%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 317,590,565, captures the company's total value, considering both debt and equity. Income quality, 0.70, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.86, gauges operational efficiency, while the research and development to revenue, 123.48%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value317,590,565
Income Quality0.70
Sales General and Administrative to Revenue0.86
Research and Development to Revenue123.48%
Capex to Operating Cash Flow0.45%
Capex to Revenue-0.96%
Capex to Depreciation-11.07%
Stock-Based Compensation to Revenue37.05%
Graham Number4.75
Return on Tangible Assets-69.36%
Graham Net Net0.24
Working Capital279,432,000
Tangible Asset Value130,987,000
Net Current Asset Value63,655,000
Invested Capital1
Average Receivables4,116,500
Average Payables11,414,000
Average Inventory17,651,500
Days Sales Outstanding9
Days Payables Outstanding98
Days of Inventory On Hand160
ROIC-52.24%
ROE-2.11%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.33, and the price to book ratio, 2.33, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.26, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -1.52, and price to operating cash flows, -1.59, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.33
Price to Book Ratio2.33
Price to Sales Ratio3.26
Price Cash Flow Ratio-1.59
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple-0.70
Price Fair Value2.33
Price to Operating Cash Flow Ratio-1.59
Price to Free Cash Flows Ratio-1.52
Price to Tangible Book Ratio0.82
Enterprise Value to Sales3.52
Enterprise Value Over EBITDA-2.45
EV to Operating Cash Flow-1.65
Earnings Yield-257.15%
Free Cash Flow Yield-180.22%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Nektar Therapeutics (NKTR) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.107 in 2024.

What is the ticker symbol of Nektar Therapeutics stock?

The ticker symbol of Nektar Therapeutics stock is NKTR.

What is company IPO date?

IPO date of Nektar Therapeutics is 1994-05-03.

What is company current share price?

Current share price is 0.900 USD.

What is stock market cap today?

The market cap of stock today is 165256200.000.

What is PEG ratio in 2024?

The current -0.016 is -0.016 in 2024.

What is the number of employees in 2024?

In 2024 the company has 137.